Postpartum depression is treated with therapy, medication, or both, depending on severity. Mild to moderate cases often improve with talk therapy alone, while moderate to severe cases typically require antidepressants. Since 2019, a newer class of fast-acting medications designed specifically for postpartum depression has also become available, offering symptom relief in days rather than weeks.
How It Gets Identified
Most cases are caught through a screening questionnaire called the Edinburgh Postnatal Depression Scale, a 10-item survey commonly given at postpartum checkups. A score above 12 or 13 out of 30 is the threshold that generally signals clinical depression rather than the temporary mood dip known as “baby blues.” That cutoff catches about 86% of true cases. If you score high, the next step is usually a clinical interview to confirm the diagnosis and gauge severity.
Talk Therapy
Two forms of therapy have the strongest evidence for postpartum depression: cognitive behavioral therapy (CBT) and interpersonal therapy (IPT). They work differently and suit different situations.
CBT focuses on identifying and correcting negative thought patterns. A typical course runs 6 to 12 weekly sessions. You learn to recognize distorted thinking, like the belief that you’re failing as a parent, and replace it with more realistic self-assessment. Studies show meaningful symptom improvement by about 4.5 months.
IPT zeroes in on relationship changes, role shifts, and grief, all of which are common triggers after having a baby. Sessions usually run 12 to 20 weeks. A large meta-analysis found that IPT actually outperforms CBT for perinatal depression, likely because so much of what drives postpartum distress is relational: adjusting to a new identity, navigating partner dynamics, or processing a difficult birth experience.
For mild depression, therapy alone is often enough. For moderate to severe cases, it works best when paired with medication.
Antidepressants
Standard antidepressants, specifically SSRIs, are the first-line medication for moderate to severe postpartum depression. Of all the SSRIs studied, sertraline has the most clinical evidence behind it. Fluoxetine and paroxetine are also commonly used.
The main drawback is timing. SSRIs take roughly 4 to 8 weeks to reach full effect. One trial comparing paroxetine to placebo found higher remission rates after 8 weeks, which is consistent with how these drugs perform in general depression. For someone in crisis with a newborn, that waiting period can feel very long, which is one reason newer treatments have generated so much interest.
Antidepressants and Breastfeeding
This is one of the biggest concerns new mothers raise, and the evidence is reassuring. Sertraline and paroxetine are considered the safest options during breastfeeding. Both transfer into breast milk at low levels, but the amount that actually reaches the infant is minimal. In a pharmacology study measuring drug levels in breastfed babies, sertraline was undetectable in all 15 infants tested. Paroxetine was undetectable in 8 out of 9. Both had a relative infant dose under 10%, the standard safety threshold. Citalopram transfers at slightly higher rates and can reach detectable levels in infants when the mother’s dose is 20 mg per day or higher, making it a less preferred choice during breastfeeding.
Fast-Acting Medications for PPD
Traditional antidepressants were developed for major depression generally, not for postpartum depression specifically. The biology behind PPD is different. During pregnancy, levels of a brain chemical called allopregnanolone rise dramatically. This compound calms brain activity by enhancing the function of inhibitory receptors. After delivery, allopregnanolone plummets, and in some women, the brain can’t adjust. The result is the severe mood disruption of postpartum depression.
Two newer medications work by mimicking allopregnanolone, restoring the calming signal that the brain lost after birth. They can improve symptoms within hours to days, a stark contrast to the weeks required by SSRIs.
Brexanolone (IV Infusion)
Approved by the FDA in 2019, brexanolone was the first drug developed specifically for postpartum depression. It’s given as a continuous IV infusion over 60 hours (2.5 days) in a healthcare facility. The dose ramps up gradually, plateaus, then tapers back down before the infusion ends.
The requirements are significant. A healthcare provider must be present on site for the entire infusion. You’re monitored continuously with a pulse oximeter because of the risk of sudden sedation or drops in oxygen levels. Sedation checks happen every 2 hours during waking periods, and if you become excessively drowsy, the infusion is paused. You must also be accompanied during any interactions with your baby while receiving treatment, since sudden loss of consciousness is possible. If oxygen levels drop, the infusion is stopped permanently.
Despite these constraints, brexanolone represented a breakthrough because it could reduce severe symptoms within days. For women who were not responding to other treatments, that speed was transformative.
Zuranolone (Oral Pill)
In August 2023, the FDA approved zuranolone as the first oral medication specifically for postpartum depression. It works through the same biological mechanism as brexanolone but doesn’t require hospitalization. The recommended dose is 50 mg once daily, taken in the evening with a fatty meal (which helps absorption), for just 14 days. That’s the entire course of treatment: two weeks of pills.
This is a fundamentally different model from SSRIs, which are typically taken for months. Zuranolone’s short treatment window and rapid onset make it a practical option for new mothers managing the demands of infant care.
Estrogen Therapy
Because the hormonal crash after delivery plays a central role in PPD, researchers have explored whether replacing estrogen could treat it. The evidence is promising but limited. In one randomized trial, women receiving estrogen patches showed rapid improvement during the first month, with an 80% remission rate by month three compared to 31% in the placebo group. However, nearly half the women in that study were also taking antidepressants, making it hard to isolate estrogen’s contribution.
Smaller open studies using sublingual estradiol showed all participants reaching recovery by 8 weeks, though again, many were on concurrent antidepressants. Estrogen therapy for PPD is not a standard recommendation at this point, but it remains an area of active clinical interest, particularly for women with documented low estrogen levels after delivery.
Peer Support
Organized peer support, where trained volunteers who have experienced postpartum depression provide regular phone contact, has measurable benefits. In a large randomized trial, women who received peer support were about half as likely to have depression scores above the clinical threshold at 12 weeks compared to those who didn’t. There was also a trend toward lower anxiety in the supported group. About 83% of participants said they would recommend the experience to a friend.
Interestingly, the number and frequency of contacts mattered. Women who were still struggling at 12 weeks had significantly more peer volunteer interactions than those who had improved, suggesting that women in greater need naturally leaned into the support more heavily. Nearly a third of the peer volunteer relationships continued beyond the structured 12-week period, becoming an ongoing source of connection. For every eight women who received peer support in the trial, one case of postpartum depression was prevented.
Choosing a Treatment Approach
Severity drives the decision. Mild postpartum depression often responds well to therapy alone, particularly IPT, with improvement over several weeks to a few months. Moderate cases typically benefit from combining therapy with an SSRI, though the 4 to 8 week wait for medication effects requires patience. Severe cases, especially those involving an inability to function or care for the baby, may warrant the newer fast-acting options. Zuranolone’s 14-day oral course has made rapid treatment far more accessible than the hospital-based brexanolone infusion, though both remain options.
Peer support works well as a supplement to any of these approaches. It doesn’t replace professional treatment for clinical depression, but the social connection and shared experience address the isolation that makes postpartum depression so much harder to endure alone.